DNDN Description — Dendreon Corp
Dendreon is a biotechnology company focused on the discovery, development and commercialization of therapeutics for cancer treatment. PROVENGE® (sipuleucel-T) is Co.'s commercialized product, and is an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. Co. owns worldwide rights for PROVENGE. Other product candidates under development include investigational cellular immunotherapies for the treatment of patients with bladder, breast, ovarian and other solid tumors; renal cell carcinoma; and colorectal and other cancers.